SCHEMBL4258015

SCHEMBL4258015

O=C(NS(=O)(=O)C=Cc1cccnc1)c1ccc(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
NFE2L2 Q16236 2/20 0.51
MEN1 O00255 1/20 0.49
FLT1 P17948 7/20 0.48
FLT4 P35916 7/20 0.48
KDR P35968 7/20 0.48
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
NAMPT P43490 2/20 0.47
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP1B1 Q16678 1/20 0.46
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258004 1.00 KMT2A (0.60) KMT2ANFE2L2MEN1FLT1FLT4
SCHEMBL4260866 0.89 KMT2A (0.47) KMT2ANFE2L2MEN1FLT1FLT4
SCHEMBL4262710 0.89 NFE2L2 (0.49) KMT2ANFE2L2MEN1FLT1FLT4
SCHEMBL4256693 0.89 CYP11B2 (0.57) KMT2ANFE2L2FLT1FLT4KDR
SCHEMBL4256696 0.89 CYP11B2 (0.57) KMT2ANFE2L2FLT1FLT4KDR
SCHEMBL4260871 0.89 KMT2A (0.47) KMT2ANFE2L2MEN1FLT1FLT4
SCHEMBL4262715 0.89 NFE2L2 (0.49) KMT2ANFE2L2MEN1FLT1FLT4
SCHEMBL4265083 0.87 FLT1 (0.50) KMT2AFLT1FLT4KDR
SCHEMBL4265077 0.87 FLT1 (0.50) KMT2AFLT1FLT4KDR
SCHEMBL4261617 0.86 NAMPT (0.53) KMT2ANFE2L2FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
EP-1904471-A1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-02 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
WO-2007006459-A1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 KMT2A 2988/4885NFE2L2 270/4885MEN1 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.